Rhythm touts Phase 3 win for rare obesity drug in people with brain damage
Rhythm Pharmaceuticals is looking to expand the potential market for its rare obesity treatment Imcivree beyond genetic disorders. The company said Monday the medicine reduced body weight in a...
View ArticleADC startup DualityBio seeks Hong Kong IPO amid precarious market
Multi-partnered ADC startup Duality Biologics is moving forward with its initial public offering plans on the Hong Kong Stock Exchange (HKEX). DualityBio expects to get net proceeds of about $176...
View ArticleLexeo discloses new data for heart drug; Spark Therapeutics to lay off workers
Plus, news about Kashiv BioSciences: Lexeo Therapeutics reveals early data for heart disease drug: The New York biotech said LX2006 produced “clinically significant improvements” in heart function...
View ArticleRayThera secures $110M in Series A raise
RayThera has collected $110 million in a Series A raise to help it advance a preclinical pipeline of small molecule drugs for immunological diseases. The San Diego-based biotech will use the proceeds...
View ArticleStock market melts down over Trump’s tariffs, and biotech's pain keeps growing
As President Donald Trump’s tariffs roil financial markets, biopharma is no exception. The XBI, an index fund viewed as the biotech’s market barometer, was down 3% in early trading Monday after closing...
View ArticleRFK Jr. won’t testify before key Senate committee this week on HHS overhaul
HHS Secretary Robert F. Kennedy Jr. won’t be appearing before a Senate panel on Thursday to testify on the massive restructuring of the health agency, despite an invitation from the committee’s...
View ArticleDrug tool and packaging makers to feel brunt of Trump tariffs, analysts say
Pharma tool and packaging production companies are readying themselves for direct impact from President Donald Trump’s tariffs, which could then have a knock-on effect on their biopharma and CDMO...
View Article‘This is self-inflicted’: Leerink’s David Risinger on the market shock and...
As the markets continued to fall Monday in response to the Trump administration’s tariff proposals, biotech has particularly been hit hard. The industry was already being hammered by firings at the FDA...
View ArticleRare disease hub at CDER and CBER faces new reality with staff crunch
Amy Comstock Rick joined the FDA last November, and she not only survived the widespread staff cuts last week, she's one of only a handful of FDA officials to speak at a live conference since ...
View ArticlePureTech rejects cash exit proposal from Nordic Capital after deal talks
PureTech Health, a Boston biopharma company that has created drug developers like Karuna Therapeutics and Seaport Therapeutics, confirmed on Monday that it was in discussions with Nordic Capital...
View ArticleFederal judge in Minnesota dismisses drugmakers' 340B lawsuits
A federal judge in Minnesota knocked down challenges from two drugmakers against a state law that the companies argued overly expanded the scope of the government's 340B drug discount program. Judge...
View ArticleHHS says it may revisit policy for anti-obesity drugs
The government said it “may consider future policy options” for anti-obesity medications, after declining to finalize a Biden-era proposal that would have expanded coverage to millions of Medicare...
View ArticleTrump administration hikes Medicare Advantage payments by $25B
The Trump administration will hike payments to Medicare Advantage insurers by more than $25 billion next year, according to an annual rate announcement released Monday afternoon. CMS said payments to...
View ArticleUS commission calls for $15B biotech investment to blunt China
A congressional commission is calling for at least a $15 billion federal investment in America’s biotechnology sector, warning that the US could soon be eclipsed by China in a key frontier of...
View ArticleExclusive: Merida Biosciences gets $121M to treat autoimmune and allergy...
A scrappy team of drug developers has come together to create new medicines for patients with autoimmune diseases and allergies. They're going after the bustling subfield of Graves' disease and also...
View ArticleCartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis
Cartesian Therapeutics said its autologous CAR-T therapy has shown “sustained benefits” in people with a rare autoimmune disease, according to the latest data cut from a Phase 2b trial. Four out of 12...
View ArticleQ&A: Lundbeck’s head of R&D on letting ‘biology speak’ in neuroscience
Johan Luthman has been running R&D at Lundbeck since 2019, and part of the neuroscience leader’s remit is helping steer development of a promising but still-experimental seizure medication that the...
View ArticleRallybio ends development in rare disorder; ImmunityBio raises $75M
Plus, news about KalVista, Kaken Pharmaceutical, Lyell and Tango Therapeutics: Rallybio stops work on RLYB212: The company had been testing the drug to see if it could prevent fetal and neonatal...
View ArticleNovo Nordisk, HHS clash in court over IRA drug selection
Novo Nordisk focused on a unique argument in federal appeals court on Tuesday in a case that will consider the extent to which the judiciary can review which drugs HHS says are eligible for Medicare ...
View ArticleKennedy's FDA cuts raise questions about 'trigger' for user fees
Last week's thousands of FDA job cuts will take a major chunk out of what the agency spends each year as part of its nearly $7 billion budget. But they could — theoretically — also have other ...
View ArticleWhat stock market chaos means for health tech
The markets have been volatile over the past few days, turned upside down by the tariffs announced by President Donald Trump. No industry has been spared. Our corner of health ...
View ArticleNIH appeals nationwide block on indirect cost cuts
The Trump administration on Tuesday said it will challenge a federal judge’s order that blocks its planned 15% rate limit on indirect cost reimbursements for NIH grant recipients nationwide. The...
View ArticleHouse panel mulls ways to boost struggling biosimilar market
The state of the US biosimilar market isn't as healthy as it should be despite significant advances in the past decade, health policy experts told a House panel on Tuesday. The US still struggles to ...
View ArticlePharma CEOs warn EU of potential US exodus as trade war continues
Executives of major pharmaceutical companies warned the European Union that they’re likely to take the US’ side amid the threat of new tariffs. The European Federation of Pharmaceutical Industries and...
View Article